Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | SPR | P35270 | 3/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1817756 | 0.79 | KMT2A (0.40) | LMNASPRKMT2AMAPT | |
| SCHEMBL1817042 | 0.73 | L3MBTL1 (0.41) | LMNASMN1; SMN2GAANPC1RAB9A | |
| SCHEMBL6899970 | 0.71 | LMNA (0.35) | LMNASPRKMT2AMAPT | |
| SCHEMBL7734302 | 0.67 | LMNA (0.34) | LMNASPRKMT2AMAPTALDH1A1 | |
| SCHEMBL15799985 | 0.63 | RAB9A (0.34) | LMNAGAANPC1RAB9AKMT2A | |
| SCHEMBL432792 | 0.62 | KMT2A (0.52) | LMNASMN1; SMN2GAASPRKMT2A | |
| SCHEMBL493850 | 0.61 | MAPT (0.45) | LMNASMN1; SMN2GAASPRKMT2A | |
| SCHEMBL16675316 | 0.60 | KMT2A (0.37) | LMNASPRKMT2AMAPT | |
| SCHEMBL12914999 | 0.60 | KMT2A (0.37) | LMNASPRKMT2AMAPT | |
| SCHEMBL435036 | 0.60 | KMT2A (0.44) | LMNAGAASPRKMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8754207-B2 | Process for the preparation of rapamycin derivatives | CADILA HEALTHCARE LIMITED (IN) | 2014-06-17 | — | — | US | disclosed |
| US-8754207-B2 | Process for the preparation of rapamycin derivatives | CADILA HEALTHCARE LIMITED (IN) | 2014-06-17 | — | — | US | disclosed |
| US-8754207-B2 | Process for the preparation of rapamycin derivatives | CADILA HEALTHCARE LIMITED (IN) | 2014-06-17 | — | — | US | disclosed |
| US-20120202988-A1 | PROCESS FOR THE PREPARATION OF RAPAMYCIN DERIVATIVES | CADILA HEALTHCARE LIMITED (IN) | 2012-08-09 | — | — | US | disclosed |
| US-20120202988-A1 | PROCESS FOR THE PREPARATION OF RAPAMYCIN DERIVATIVES | CADILA HEALTHCARE LIMITED (IN) | 2012-08-09 | — | — | US | disclosed |
| US-20120202988-A1 | PROCESS FOR THE PREPARATION OF RAPAMYCIN DERIVATIVES | CADILA HEALTHCARE LIMITED (IN) | 2012-08-09 | — | — | US | disclosed |
| WO-2011051960-A2 | PROCESS FOR THE PREPARATION OF RAPAMYCIN DERIVATIVES | CADILA HEALTHCARE LIMITED (IN) | 2011-05-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120202988-A1 | PROCESS FOR THE PREPARATION OF RAPAMYCIN DERIVATIVES | RICTOR, MTOR, RPTOR | LMNA 4108/4885SMN1; SMN2 2639/4885GAA 2129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.